Journal Information
Vol. 11. Issue 6.
Pages 573-586 (November - December 2005)
Share
Share
Download PDF
More article options
Vol. 11. Issue 6.
Pages 573-586 (November - December 2005)
Clinical Case
Open Access
Linfangioleiomiomatose: A propósito de um caso clínico
Lymphangioleiomyomatosis: A case report
Visits
4793
António Santos Costa1,
Corresponding author
Amsantoscosta@gmail.com

Correspondência: António Santos Costa. Exames Especiais de Pneumologia, Centro Hospitalar de Vila Real / Peso da Régua. Av. da Noruega, 5000 – Vila Real
, Rafael Noya1, Teresa Campos Calvo2, R. Severo3, Abel Afonso4
1 Interno Complementar de Pneumologia do Centro Hospitalar de Vila Real / Peso da Régua.
2 Assistente Hospitalar Graduada de Pneumologia do Centro Hospitalar de Vila Real / Peso da Régua.
3 Assistente Hospitalar Graduada de Ginecologia / Obstetrícia do Centro Hospitalar de Vila Real / Peso da Régua.
4 Director do Serviço de Pneumologia do Centro Hospitalar de Vila Real / Peso da Régua.
This item has received

Under a Creative Commons license
Article information
Resumo

A linfangioleiomiomatose (LAM) é uma doença rara, de etiologia não esclarecida, que afecta mulheres, principalmente em idade reprodutiva. É caracterizada pela proliferação não neoplásica de células musculares lisas que ao longo do tempo podem obstruir as vias aéreas, vasos sanguíneos e linfáticos.

Os AA descrevem um caso de LAM e a sua evolução ao longo de nove anos. Este caso clínico apresenta algumas particularidades, nomeadamente o agravamento de hemoptises no contexto de uma gravidez e a evolução sem tosse nem episódios de pneumotórax. A terapêutica hormonal não pareceu influenciar as hemoptises nem a deterioração gradual da função pulmonar. Os autores procedem a uma revisão da literatura a propósito deste caso clínico.

Rev Port Pneumol 2005; XI (6): 573-585

Palavras-chave:
Linfangioleiomiomatose
hemoptises
gravidez
Abstract

Lymphangioleiomyomatosis (LAM) is a rare disease of unknown etiology affecting woman, primarily in their reproductive years. It is characterized by non-neoplasic proliferation of atypical smooth muscle cells that may lead to airway, lymphatic and blood vessel obstruction over time.

A nine-year followed-up case of LAM is described, which presents with some unusual details as worsening haemoptysis in the setting of pregnancy and absence of cough or pneumothorax along the course of the disease. Neither haemoptysis nor gradual pulmonary function deterioration seemed to be influenced by hormone therapy. A brief review of the disease is then presented.

Rev Port Pneumol 2005; XI (6): 573-585

Key-words:
Lymphangioleiomyomatosis
haemoptysis
pregnancy
Full text is only aviable in PDF
Bibliografia
[1.]
S.R. Johnson, A.E. Tattersfield.
Clinical experience of lymphangioleiomyomatosis in the UK.
Thorax, 55 (2000), pp. 1052-1057
[2.]
T. Urban, R. Lazor, J. Lacronique, M. Murris, S. Labrune, D. Valeyre, et al.
Pulmonary lymphangioleiomyomatosis – a study of 69 patients.
Medicine, 78 (1999), pp. 321-327
[3.]
J. Kelly, J. Moss.
Lymphangioleiomyomatosis.
Am J Med Sci, 321 (2001), pp. 17-25
[4.]
R.E. Sobonya, S.F. Quan, J.S. Fleishman.
Pulmonary lymphangioleiomyomatosis: quantitative analysis of lesions producing airflow limitation.
Hum Pathol, 16 (1985), pp. 1122-1128
[5.]
G. Flores-Delgado, P. Bringas, S. Buckley, K.D. Anderson, D. Warburton.
Non genomic strogen action in human lung myofibroblasts.
Biochem Biophys Res Commun, 283 (2001), pp. 661-667
[6.]
T. Hayashi, M.V. Fleming, W.G. Stetler-Stevenson, L.A. Liotta, J. Moss, V.J. Ferrans, et al.
Immunohistochemical study of matrix metalloproteinases (MMP) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM).
Hum Pathol, 28 (1997), pp. 1071-1078
[7.]
M.H. Colley, E. Geppert, W.A. Franklin.
Immunohistochemical detection of steroid receptors in a pulmonary lymphangioleiomyomatosis (LAM).
Hum Pathol, 28 (1997), pp. 1071-1078
[8.]
E. Nussbaun, P. Grancy, J. Finklestein.
Early onset of childhood pulmonary lymphangioleiomyomatosis.
Clin Pediatr, 27 (1998), pp. 279-284
[9.]
S. Baldi, M. Papotti, M.L. Valente, M. Rapellino, E. Scappaticci, B. Corrin.
Pulmonary lymphangioleiomyomatosis in postmenopausal women: report of two cases and review of the literature.
Eur Resp J, 7 (1994), pp. 1013-1016
[10.]
H.W. Kang, C. Kim, K.S. Kang, K.S. Lee, C.S. Lee, Y.H. Kim.
Pulmonary lymphangioleiomyomatosis in a male.
J Korean Med Sci, 6 (1991), pp. 83-85
[11.]
J.R. Taylor, J. Ryu, T. Colby, T.A. Raffin.
Lymphangioleiomyomatosis: clinical course in 32 patients.
N Engl J Med, 323 (1990), pp. 1254-1260
[12.]
M. Kitaichi, K. Nishimura, H. Itoh, T. Izumi.
Pulmonary lymphangioleiomyomatosis: a report of 46 patients, including a clinicopathologic study of prognostic factors.
Am J Respir Crit Care Med, 151 (1995), pp. 527-533
[13.]
M.L.S. Stávale, C.R.R. Carvalho, R.A. Kairalla, M.M. Brentani, V.C. Delmonte, J.V. Barbas Filho.
Linfogioleiomiomatose pulmonar – apresentação de seis casos e revisão da literatura.
J Pneumol, 16 (1990), pp. 187-192
[14.]
H. Kreisman, Y. Robitaille, G.P. Dionne, M.J. Palayew.
Lymphangioleiomyomatosis syndrome with hyperparatyreoidism: a case report.
Cancer, 42 (1978), pp. 364-372
[15.]
C.C. Yockey, R.E. Riepe, K. Ryan.
Pulmonary lymphangioleiomyomatosis complicated by pregnancy.
Kans Med, 87 (1986), pp. 277-278
[16.]
A.I.I. Eliasson, Y.Y. Phillips, M.F. Tenholder.
Treatment of lymphangioleiomyomatosis: a meta-analysis.
Chest, 96 (1989), pp. 1352-1355
[17.]
T. Urban, F. Kutten, A. Gompel, J. Marsac, J. Lacronique.
Pulmonary lymphangioleiomyomatosis: follow-up and long term outcome with antiestrogen therapy: a report of eight cases.
Chest, 102 (1992), pp. 472-476
[18.]
A. Shen, M.D. Iseman, J.A. Waldron, T.E. King.
Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous estrogens.
Chest, 91 (1987), pp. 782-785
[19.]
I. Wahedna, S. Cooper, J. Williams, I.C. Paterson, J.R. Britton, A.E. Tattersfield.
Relation of pulmonary lymphangioleiomyomatosis to use of oral contraceptive pill and fertility in the UK: a national case control study.
Thorax, 49 (1994), pp. 910-914
[20.]
K.S. McCarthy Jr., J.A. Mossler, R. McLelland, H.O. Sieker.
Pulmonary lymphangioleioyomatosis responsive to progesterone.
N Engl J Med, 303 (1980), pp. 1461-1465
[21.]
A. Zanella, P. Toppan, D. Nitti, M. Lise.
Pulmonary lymphangioleiomyomatosis: a case report in postmenopausal women treated with pleurodesis and progesterone (medroxyprogesterone acetate).
Tumori, 82 (1996), pp. 96-98
[22.]
G.A. Rossi, B. Balbi, S. Oddera, S. Lantero, C. Ravazzoni.
Response to treatment with an analog of the luteinizing-releasinghormone in a patient with pulmonary lymphangioleiomyomatosis.
Am Rev Respir Dis, 143 (1991), pp. 174-176
[23.]
J.D. O’Brien, J.H. Luin, J.F. Parosa, B.R. Deyoung, M.R. Wick, P. Trulock.
Lymphangioleiomyomatosis recurrence in the allograft after single-lung transplantation.
Am J Respir Crit Care Med, 151 (1995), pp. 2033-2036
[24.]
B. Corrin, A.A. Liebow, P.J. Friedman.
Pulmonary, lymphangioleiomyomatosis: a review.
Am J Pathol, 79 (1975), pp. 348-367
[25.]
P. Medeiros Jr., C. Carvalho.
Linfangioleiomiomatose pulmonar.
J Bras Pneumol, 30 (2004), pp. 66-77
[26.]
E.S. Roach, M. Smith, P. Huttenlocher, M. Bhat, D. Alcorn, L. Hawley.
Report of the diagnostic criteria committee of the National Tuberous Sclerosis Association.
J Child Neurol, 7 (1992), pp. 221-224
[27.]
T.A. Smolarek, L.L. Wessner, F. McCormackx, J.C. Mylet, A.G. Menon, E.P. Henske.
Evidence that lymphangioleiomyomatosis is caused by TSC 2 mutations: chromossome 16 p 13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangioleomyomatosis.
Am J Hum Gent, 62 (1998), pp. 810-815
Copyright © 2005. Sociedade Portuguesa de Pneumologia/SPP
Download PDF
Pulmonology
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?